Hendrik Treede

Hendrik Treede

Auto-generated profile, based on publicly available information

Hendrik Treede

Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
HTHendrik Treede
Hendrik Treede
AGAllan R. Glanville
Allan R. Glanville
WKWalter Klepetko
Walter Klepetko
CAChristina Aboyoun
Christina Aboyoun
EVEik Vettorazzi
Eik Vettorazzi
HRHermann Reichenspurner
Hermann Reichenspurner

16 April 2012 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
HTHendrik Treede
Hendrik Treede
FMFriedrich-Wilhelm Mohr
Friedrich-Wilhelm Mohr
SBStephan Baldus
Stephan Baldus
ARArdawan Rastan
Ardawan Rastan
SEStephan Ensminger
Stephan Ensminger
HFHans-Reiner Figulla
Hans-Reiner Figulla
Transcatheter aortic valve implantation (TAVI) has shown promising results in patients with severe aortic stenosis (AS) at high risk for conventional heart surgery. The safety and efficacy of transapical aortic valve implantation using the JenaValve™, a second-generation TAVI device, were evaluated. The system consists of a tested porcine root valve mounted on a nitinol stent with feeler-guided positioning and clip fixation on the diseased leaflets. This multicentre, prospective, single-arm study, conducted at seven German sites, enrolled 73 patients (mean age 83.1 ± 3.9), European System for Cardiac Operative Risk Evaluation (EuroSCORE) (28.4 ± 6.5%) of whom 67 patients underwent elective TAVI. Three sizes were used for annular diameters up to 23 mm (n = 21), 25 mm (n = 31) and 27 mm (n = 15). Clinical and echocardiographic evaluations were performed at baseline, post-procedure, discharge and 30 days, and also at 3, 6 and 12 months. The primary endpoint was all-cause mortality at 30 days. Secondary endpoints were procedural success, major adverse cardiac and cerebrovascular events and echocardiographic performance. TAVI with the JenaValve™ device was successful in 60 patients (procedural success rate 89.6%). The overall mortality at 30 days was 7.6%. Conversion to surgery was necessary in four patients (6%), two patients underwent valve-in-valve implantations (3%), one patient was withdrawn per protocol after conversion to TAVI using a balloon-expandable valve (1.5%) since the patient did not receive the study device. Perioperative stroke occurred in two cases (3%). Pacemaker implantation for new onset conduction disorders was necessary in six patients (9.1%). No ostial coronary obstructions were seen. Post-procedure TAVI resulted in favourable reduction of mean transvalvular gradients (40.6 ± 15.9 vs. 10.0 ± 7.2 mmHg, P < 0.0001) and increase in valve opening area (0.7 ± 0.2 vs. 1.7 ± 0.6 cm², P < 0.0001). The majority of successfully treated patients revealed no or minimal paravalvular aortic regurgitation (86.4%); none of the patients had severe post-procedural regurgitation (>2+). Transapical JenaValve™ implantation was safe and effective in the treatment of severe AS in elderly patients at high risk for surgery. Active clip fixation on the native leaflets and anatomically correct feeler-guided positioning led to good functionality and prevented ostial coronary impairment. Implantation without the need for rapid pacing prevented haemodynamic compromise during valve implantation.

1 January 2012 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
HTHendrik Treede
Hendrik Treede
JSJohannes Schirmer
Johannes Schirmer
VRVolker Rudolph
Volker Rudolph
OFOlaf Franzen
Olaf Franzen
MKMalgorzata Knap
Malgorzata Knap
HRHermann Reichenspurner
Hermann Reichenspurner

1 September 2012 in EuroIntervention
Verified
Journal Article
Closed access
HTHendrik Treede
Hendrik Treede
ARArdawan Rastan
Ardawan Rastan
Markus Wolfgang FerrariMarkus Wolfgang Ferrari
Markus Wolfgang Ferrari
SEStephan Ensminger
Stephan Ensminger
HFHans-Reiner Figulla
Hans-Reiner Figulla
FMFriedrich-Wilhelm Mohr
Friedrich-Wilhelm Mohr
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 October 2010 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
HTHendrik Treede
Hendrik Treede
TTThilo Tübler
Thilo Tübler
HRHermann Reichenspurner
Hermann Reichenspurner
EGEberhard Grube
Eberhard Grube
APAndrea Pascotto
Andrea Pascotto
JSJoachim Schofer
Joachim Schofer

7 October 2015 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
PDF file
HTHendrik Treede
Hendrik Treede
BRBeate Reiter
Beate Reiter
USUlrich Schaefer
Ulrich Schaefer
SBStefan Blankenberg
Stefan Blankenberg
HRHermann Reichenspurner
Hermann Reichenspurner
LCLenard Conradi
Lenard Conradi
Objectives Biological prostheses for surgical aortic valve replacement (sAVR) are increasingly being considered in patients < 60 years of age. Likely, preserving the option of performing a transcatheter valve-in-valve (ViV) procedure in cases of structural valve deterioration has contributed to this development. We assessed the use pattern in sAVR over an 11-year period. Methods From 2002 through 2012, a total of 3,172 patients underwent sAVR at our center. Results Mean age was 70.4 ± 10.6 years and mortality was 1.9%. From 2002 to 2012, mean manufacturer given valve size increased from 22.8 ± 1.7 to 23.9 ± 2.0 mm (p < 0.001). Mean true internal diameter and effective orifice area increased from 19.6 to 20.3 mm (p = 0.027) and 1.41 to 1.56 cm2 (p < 0.001), respectively. Use of mechanical valves decreased from 10.9 to 1.8% (p < 0.001), and patients were younger in 2012 than in 2002 (52.8 ± 16.5 vs. 41.0 ± 14.3 years; p = 0.028). Conclusion Profound change of use pattern in sAVR was observed as indication for biological prostheses became more liberal. Larger prostheses were implanted during the observational period. Especially in younger patients, optimal sizing is essential to preserve the option for subsequent ViV procedures. * Both the authors contributed equally to this work.